An EPR-independent therapeutic strategy: Cancer cell-mediated dual-drug delivery depot for diagnostics and prevention of hepatocellular carcinoma metastasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33253967.
- Also identified by DOI 10.1016/j.biomaterials.2020.120541.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Motivated by the "self-seeding" of the cancer cells, the EPR-independent nanoparticles (NPs)-based therapeutic strategy have been explored to prevent hepatocellular carcinoma metastasis in this paper, the mechanism of anti-metastasis of the NPs was also evaluated. We firstly have established an aggressive whole-body spreading orthotopic LM3 tumour model closing to actual cases of human patients and the synthesized Trojan Horse-like amphiphilic nanobowls have been engineered with dual drugs with completely different pharmacokinetic profiles for cancer cell-mediated anti-metastasis therapy. These Trojan Horse-like nanobowls can serve as dual-drug delivery depots for site-specific pH/NIR dual-stimuli drug release with effectively suppressed primary tumor growth and metastases. Furthermore, the multi-mode UCL/MR/CT imaging is competent for providing comprehensive and valuable information for evaluating and adjusting the treatment. The employ of cancer cell-mediated anti-metastasis therapeutic strategy delivering drugs into metastatic cells to defeat tumor metastases provides directions in the fields of anti-metastasis therapy.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Nanoparticles
- Pharmaceutical Preparations